Receive a copy of our current research models and services product guide.
Revolutionize Drug Discovery with Inotiv’s Comprehensive Neuroscience Program
Target Sufficiency® enables direct, quantitative analysis of drug target systems in cells, biofluids, tissues, and tissue models, including formalin-fixed, paraffin-embedded (FFPE) tissues.
Reduce costs with our complimentary sample for evaluation in your lab.
Search by therapeutic area, research phase, and products and services at inotiv.com.
Inotiv delivers a broad array of nonclinical and analytical services from discovery through clinical development.
Inotiv provides the broadest range of research models and related services to pharmaceutical and biotech companies, government, academia, and other life science organizations.
Tuesday, February 11, 2025 Webinar 11:00 am EST Compassion fatigue is a prevalent issue that poses significant challenges to the well-being of lab animal science professionals. Rec...
March 6, 2025 11 am–12 pm EDT Online webinar Lipid nanoparticles (LNPs) have emerged as popular vehicles for delivering various types of drugs such as mRN...
March 10-14, 2025 San Diego, CA Booth #5101 The Annual Meeting is where you learn first-hand from leaders in the field through interactive, engaging sessions. It's the place to get...
February 05, 2025 Enhanced liquidity by $27.5 million through the issuance of ...
January 22, 2025 WEST LAFAYETTE, Ind., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”),
December 30, 2024 WEST LAFAYETTE, Ind., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization...
How Differences Between Experimental IBD Models Can Impact Your Drug Development Program
Due to the current FDA concern and guidance on reducing the risk of Nitrosamine impurities in human drugs, there has been an increased industry need for testing of these impurities using the Bacterial Reverse Mutation (Ames) test. As Nitrosamines are not readily detectable by standard Ames methodologies, specifically cited in the Ames testing guideline (OECD 471), the need for a robust protocol better suited for this class of compounds is warranted.
Copyright © 2025 Inotiv. All Rights Reserved.